en.autobio.com.cnCrawled Nov 12, 2026
CAIVD interviewed Mr. Zhang Ruifeng, the leader of 2023, deputy general manager and strategic director of Autobio.
Autobio showcases in vitro diagnostic products at WHX Labs Dubai 2026.
Autobio provides comprehensive product solutions and services for medical laboratories. The company listed on the Shanghai Stock Exchange in 2016 and holds certifications for innovation platforms like the National Enterprise Technology Center. It has over 850 product registrations, 1,700+ patents, and a 2024 revenue of 44.71 billion yuan. Its in vitro diagnostics park spans 251+ acres with research, manufacturing, and storage facilities.
With 20+ years of expertise and ISO 13485 certification, Autobio specializes in IVD reagents and instruments for immunoassay, microbiology, and biochemistry testing.
Autobio Diagnostics
。
Autobio Diagnostics Co., Ltd. reports **CNY 1.48 basic and diluted earnings per share** for the nine months ended September 30, 2026, a slight decline from **CNY 1.5** in the same period the prior year. The results cover continuing operations only. The company provides diagnostic solutions in the biotechnology sector.
Oct 2026MarketScreenerNews article
Autobio Diagnostics Co., Ltd. reports **CNY 2,057.93 million in sales and revenue** for the half-year ending June 30, 2026, marking a slight decline from **CNY 2,060.31 million** in the same period the prior year. The company provides diagnostic services and products, though no specific growth drivers or segment details are disclosed in the earnings update. Financial performance remains stable with marginal year-over-year changes.
Aug 2026MarketScreenerNews article
Autobio Diagnostics partners with Vietnam Private Medical Association (VPMA) and Hop Luc Group to strengthen its presence in Vietnam’s private healthcare sector. The agreements mark the company’s strategic move into the global in vitro diagnostics (IVD) market. This expansion targets Vietnam’s growing demand for advanced diagnostic solutions.
Apr 2026Insight, China's Pharmaceutical IndustryNews article
Autobio Diagnostics Co., Ltd. reports **CNY 3,380.04 million in sales and revenue** for the nine months ending September 30, 2024, marking a year-over-year increase from CNY 3,242.5 million. The company’s financial results reflect growth in its core operations during the period. The earnings update highlights performance trends in its diagnostic services segment.
Oct 2024MarketScreenerNews article
